GSK plc (GSK,GSK.L) said that the Center for Drug Evaluation (CDE) of the National Medical Products Administration or NMPA in China has granted Breakthrough Therapy Designation to Blenrep (belantamab mafodotin) in combination with bortezomib and dexamethasone or BorDex for the treatment of relapsed or refractory multiple myeloma.
The Breakthrough Therapy Designation was granted based on the interim results of the phase III head-to-head DREAMM-7 trial, which met its primary endpoint, showing statistically significant and clinically meaningful improvements in progression-free survival (PFS) for belantamab mafodotin combined with BorDex compared to daratumumab plus BorDex in relapsed or refractory multiple myeloma.
Multiple myeloma is the third most common blood cancer globally and is generally considered treatable but not curable.There are approximately more than 180,000 new cases of multiple myeloma diagnosed globally each year.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.